SAN DIEGO, Jan. 21, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapeutics for oncology and rare diseases, today announced preliminary efficacy and safety data from the Phase...
Hence then, the article about inhibrx biosciences announces preliminary data from the phase 1 trial of ozekibart inbrx 109 for the treatment of colorectal cancer was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Inhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the Treatment of Colorectal Cancer )
Also on site :
- Starbucks’ New ChatGPT Integration Is a Potential Privacy Nightmare
- Trader Joe's $4 Find Has Returned — Why Fans Obsess Over the Easy Dinner
- 1980s Rock Band Announces Brand New Album but There's a Twist